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several reasons. First, aS is the primary (but not the
only) protein component of the Lewy body and Lewy
neurite deposits that are found in the brains of the
victims of Parkinson's disease (PD). Second, genet-
ic lesions resulting in either increased levels of wild-
type aS or point mutations in aS cause Parkinson-
ism. Third, aS is one of the earliest identified and
best characterized members of the recently recog-
nized class of intrinsically disordered proteins.
Despite immense interest in aS, many questions
remain regarding both the precise pathogenic role of
aS in PD and the normal physiological functions of
the protein, which appear to include a role at the
synapse, likely involving binding to synaptic vesicles
and somehow modulating their biogenesis, traffick-
ing, or exocytosis, and possibly also an uncharac-
terized role at the nuclear envelope membrane. A
key aspect of aS function appears to be membrane
binding, and the primary sequence of the protein
reflects this through the presence of seven imperfect
11-residue tandem repeats, with a central consen-
sus motif of KTKEGV, that are characteristic of
several classes of proteins that bind to membranes
in a reversible fashion, including the apolipoproteins.
These repeats are contained within the ~100 N-
terminal residues of the protein, which constitute the
lipid-binding domain (LBD) of aS and thereby
manifest a known aspect of aS function. Interesting-
ly, the primary site responsible for aS aggregation
into amyloid fibrils, the so-called NAC region
(residues 61–95), is also located within the LBD.
C-terminal to its LBD, aS contains an additional
~40 residues that are commonly referred to as its C-
terminal tail (CTT). The most remarkable physico-
chemical characteristic of the CTT is its negative
charge content, which at neutral pH arises from 14
negatively charged side chain as well as the C-
terminal carboxyl group. Interestingly, the CTT alsofeatures two 16-residue tandem pseudo-repeats.1
While the LBD is known to mediate both membrane
binding and aggregation of aS, the functional and
pathogenic roles of the CTT have remained poorly
understood and highly controversial. One early func-
tional attribute assigned to the CTT was a chaperone
activity, based on observations that aS could prevent
the aggregation of other proteins in a manner that
required the CTT.2,3 While occasional reports of aS
chaperone function in vitro continue,4 it is not generally
accepted as a likely function of the protein in vivo.
Another proposed role of the CTT is metal binding,
including calcium, copper, iron, and possibly other
metals. The presence of many negatively charged
side chains in the CTT indeed leads to binding of a
variety of metal or other cations. Roles for asyn as a
copper- or iron-binding metalloreductase have been
proposed5 but have not gained widespread traction.
Calcium binding by aSmay bemore interesting given
the proposed role of aS in synaptic vesicle exocytosis
(a strongly calcium-dependent process) as well as
reported interactions of aS with the calcium-binding
protein calmodulin.6,7 Nevertheless, it appears that
metal binding by the CTT is largely nonspecific and
recapitulates what would be expected for any
polypeptide sequence of a similar amino acid
composition.8 This does not rule out a functional
role for metal binding but does make the notion less
compelling. From the viewpoint of aS pathology,
metal binding to the CTT neutralizes its highly
negative charge and thereby enhances aggregation.
The CTT has also been observed to form transient
long-range interactions with other regions of aS,
including the positively charged N-terminal region,9
and these have been proposed to be protective
against aggregation.10 Indeed, truncation11,12 or
neutralization13 of the CTT results in forms of aS
that are much more prone to aggregate. However,
the most probable explanation for this effect is that6
2394 The Mysterious C-Terminal Tail of Alpha-Synucleinthe highly negative charge of the CTT leads to
intermolecular electrostatic repulsion between synu-
clein molecules.14,15 The intramolecular interactions
of the CTT are likely too transient to provide any
significant occlusion of aggregation sites, and in fact,
an increase in such interactions is associated with
increased, rather than decreased, aggregation.14,16
Interestingly, despite general agreement that the
CTT does not interact with membranes, various
reports have suggested that this may not be entirely
true. Oxidative modifications in the CTT exert a
measurable effect on the affinity of aS for
membranes,17 and titration of aS with high concen-
trations of detergents or lipids leads to small but
measurable changes in NMR parameters, including
both chemical shifts and resonance intensities.18,19
Even phosphorylation in the CTT can influence the
membrane interactions of some aS variants.20
Some of these effects may be explained by
changes in intramolecular interactions upon lipid
binding by the N-terminal LBD, but a potential role
for the CTT in modulating aS membrane interac-
tions remains possible.
The most compelling putative function of the CTT
is to mediate protein–protein interactions. A number
of potential aS-interacting proteins have been
identified, and many of them have been reported to
interact with the CTT. A few examples include a
reported interaction with the enzyme phospholipase
D (PLD), which not only required LBD-mediated
membrane binding but also requires the CTT,21
presumably for direct interactions with PLD, perhaps
at its active site. This interaction has been called into
question,22 but the matter remains to be conclusive-
ly resolved. Other individual proteins, including tau23
and MAP-1B,24 have been reported to bind to aS via
the CTT and larger-scale efforts have identified
larger numbers of proteins that bind to the CTT in a
phosphorylation-dependent manner.25 Indeed, the
CTT contains several sites for posttranslational
modifications of aS, including phosphorylation sites
at Ser129 and Tyr125, which are likely to modulate
protein–protein interactions. Most recently, aS has
been reported to interact with glucocerebrosidase
A,26 a protein that, when mutated, confers an
increased risk of PD, and synaptobrevin-2,27 a
SNARE protein required for synaptic vesicle exocy-
tosis, through its CTT.
The CTT of aS is not part of the β-sheet-rich
structured core of the amyloid fibril aggregates
associated with PD,28–33 and indeed its accessibility
to antibodies was key to the discovery that Lewy
bodies are enriched in aS.34 Nevertheless, it is clear
that the CTT can profoundly influence the process of
aS aggregation into fibrils, as its removal greatly
increases the rate of fibril formation, as well as
influences the morphology of the resultant
fibrils.11,35 Notably, phosphorylation at Ser129 in
the CTT is considered one of the clearest markersof pathological forms of aS,36 although the role of
this modification in the aggregation and toxicity of
aS remains controversial. Furthermore, despite not
being involved in the core structure of aS
amyloids, there have been some hints that the
CTT is sensitive to the proximity of that core
structure. For example, the accessibility of epi-
topes in the CTT is modified in some fibrillar aS
aggregates compared with others,37 or compared
with unaggregated protein.38
A collaboration between the Dobson and Wyns
groups at University of Cambridge and Vrije Uni-
versiteit Brussel has now resulted in the develop-
ment of small single-domain antibody fragments,
known as nanobodies, directed against different
regions of the aS CTT. Interestingly and rather
unexpectedly, it appears that the affinity and binding
modes of these nanobodies to aS fibrils formed in
vitro depend on both their age and origin. These
differences imply both changes in the accessibility of
the CTT as fibrils mature and heterogeneous
populations of CTT structural ensembles in at least
some types of fibril assemblies. While detailed
information is available regarding the conformational
ensemble of the CTT of aS in both mature fibrils and
in its monomeric state, much less information is
available regarding its behavior in any of the
potentially numerous intermediates that likely occur
(whether off or on pathway) during fibril formation.
The initial studies using nanobodies reveal that even
relatively mature fibrillar aggregates are likely to
undergo significant structural rearrangements, con-
sistent with, for example, reports of β-strand register
changes in fibrillar species.39 Thus, the reported
nanobody reagents are likely to prove powerful tools
for probing the structural and thermodynamic prop-
erties of the CTT in many different contexts, both in
vitro and potentially in vivo, and both in the context of
pathological aS aggregation and in the context of
normal aS function.Acknowledgements
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